CORAL GABLES, Fla., Nov. 3 CatalystPharmaceutical Partners, Inc. (Nasdaq: CPRX) a biopharmaceutical company thatacquires or in-licenses, develops and commercializes prescription drugs forthe treatment of drug addiction and obsessive compulsive disorders, todayannounced that Patrick J. McEnany, Chief Executive Officer, will be presentingan overview of the Company at the Rodman & Renshaw 10th Annual GlobalInvestment Conference on Tuesday, November 11, 2008 at 10:45 am Eastern Timeat the New York Palace Hotel in New York City.
Interested parties can access a live or archived web cast of thepresentation at: http://www.wsw.com/webcast/rrshq14/cprx . The presentationwill be archived for 90 days.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical companyfocused on the development and commercialization of prescription drugs for thetreatment of addiction and obsessive compulsive disorders. The Company hasobtained from Brookhaven National Laboratory an exclusive worldwide licensefor Brookhaven's patent portfolio in the United States relating to the rightto use vigabatrin to treat a wide variety of substance addictions andobsessive compulsive disorders. Catalyst has also been granted rights toBrookhaven's vigabatrin-related foreign patents or patents pending in morethan 30 countries. The Company's initial product candidate based on vigabatrinis CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food &Drug Administration (FDA) for the treatment of cocaine addiction. Thisindicates that the FDA has recognized that CPP-109 is intended for thetreatment of a serious or life-threatening condition for which there is noeffective treatment and which demonstrates the potential to address unmetmedical needs.
For more information about Catalyst, go to www.catalystpharma.com.
This press release contains forward-looking statements. Forward-lookingstatements involve known and unknown risks and uncertainties, which may causethe Company's actual results in future periods to differ materially fromforecasted results. A number of factors, including those factors described inthe Company's Annual Report on Form 10-K for 2007 and the Company's QuarterlyReport on Form 10-Q for the quarter ended June 30, 2008 that the Company hasfiled with the U.S. Securities and Exchange Commission ("SEC"), couldadversely affect the Company. Copies of the Company's filings with the SEC areavailable from the SEC or may be obtained upon request from the Company. TheCompany does not undertake any obligation to update the information containedherein, which speaks only as of this date.
SOURCE Catalyst Pharmaceutical Partners, Inc.